• Recipient
  • Ability to give informed consent
  • Receiving FMT or other gut-related microbiota product within 90 days after providing consent
  • Access to internet and/or telephone
• Donor
  • Ability to give informed consent
  • Providing stool sample for FMT

• Incarceration

• Recipient Inclusion Criteria

  • Ability to give informed consent
  • Receiving FMT or other gut-related microbiota product within 90 days after providing consent
  • Access to internet and/or telephone

• Donor Inclusion

  • Ability to give informed consent
  • Providing stool sample for FMT

• Incarceration

• Patients 18 and older, inclusive; AND
• Patients who meet the 2013 ACR/EULAR classification criteria for systemic sclerosis; AND
• < 5 years from onset of first non-RP symptom attributed to systemic sclerosis.

• Patients under 18 years of age.
• Patients with cognitive impairment that will interfere with conducting the study. Study staff should determine if the patient, at that moment, has the cognitive capacity to understand what the study entails, assent to participate, and complete the assessments. If there is question as to whether a patient may meet this criterion, RCs/RAs should defer to the site PI trained on the study to help determine; OR
• Patients who are non-English Speaking. The patient must be able to proficiently read, speak, and understand English in order to be eligible.

• ≥ 18 years of age.
• Female patients with confirmed IBD diagnoses who are pregnant and taking immunosuppressants and/or biologic therapy.

• Pregnant female patients younger than 18 years of age.
• Confirmed multiple gestation.

Eligibility last updated 10/18/21. Questions regarding updates should be directed to the study team contact.

• Has been diagnosed with PSVT by a medical professional, and reports having at least one previous episode of PSVT. For clarity, PSVT refers to episodic SVT that includes the AV node as a critical part of reentrant circuit. 
• Is at least 18 years of age.
• Signed NODE-303 written informed consent.
• Women of child-bearing potential must be willing to use at least 1 form of contraception during the trial and must be willing to discontinue from the study should they become or plan to become pregnant. Postmenopausal females are defined as having amenorrhea for at least 12 months prior to Screening without an alternative medical cause.
• Willing and able to comply with study procedures.

• Patients with only a history of atrial arrhythmia that does not involve the atrioventricular (AV) node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial tachycardia) are not eligible. Patients with a history of these tachycardias who are also diagnosed with PSVT are eligible.
• History of allergic reaction to verapamil.
• Current therapy with digoxin, or any Class I or III antiarrhythmic drug. Patients may be eligible if these drugs are stopped at least five half-lives before the administration of etripamil NS. The only exception is oral amiodarone which must be stopped 30 days before enrollment.
• History or evidence of ventricular pre-excitation; e.g., delta waves, Wolff-Parkinson-White syndrome.
• History or evidence of a second- or third-degree AV block.
• History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes, ventricular fibrillation, or sustained ventricular tachycardia).
• Symptoms of congestive heart failure New York Heart Association Class II to IV.
• SBP < 90 mmHg at Screening, Baseline or any Follow-up Visit.
• Severe symptoms of hypotension experienced during PSVT episodes.
• Significant physical or psychiatric condition including alcoholism or drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of the patient, or impede the patient’s capacity to follow the study procedures.
• History of syncope due to an arrhythmic etiology at any time, or history in last 5 years of unexplained syncope.
• Is pregnant or breastfeeding.
• Previously enrolled in a clinical trial for etripamil and received study drug or participation in any clinical trial for other investigational products or medical devices within 30 days of Screening.
• History of ACS or stroke within 6 months of Screening.
• Evidence of renal dysfunction as determined by an estimated glomerular filtration rate assessed at the Screening Visit as follows:
  • < 60mL/min/1.73m^2 for patients < 60 years of age;
  • < 40mL/min/1.73m^2 for patients ≥ 60 and < 70 years of age;
  • < 35mL/min/1.73m^2 for patients ≥ 70 years of age.

• All patients 18 years of age and older undergoing (or who have previously undergone) EpiAcc as part of their standard clinical care for an electrophysiology procedure. Patients will not undergo EpiAcc purely for the research study.

• Patients undergoing EpiAcc for the purposes of a pericardiocentesis.

Inclusion Criteria

• Have disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment
• Any age and either gender
• Using a cord blood product manufactured by the National Cord Blood Program (at least one, if the graft contains more than one unit)

Exclusion Criteria

• Are only receiving licensed cord blood products
• Are only receiving unlicensed cord blood products from other banks
• Are being transplanted at non-US transplant centers
• Are receiving cord blood products that will be "manipulated" post-thaw (e.g., ex vivo expansion, incubation in vitro, etc.)

• Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements.
• Patient has or is intended to receive or be treated with an eligible product.
• Patient is consented within the enrollment window of the treatment/therapy received, refer to the applicable Condition/Therapy Appendix.

• Patient who is, or is expected to be inaccessible for follow-up.
• Patient with exclusion criteria required by local law.
• Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results (i.e., no required intervention that could affect interpretation of all-around product safety and or effectiveness).

• Age 18 and older.
• Willing to provide consent.
• Men or women.
• Stable weight for 3 months prior to study entry.

• Individuals who are unable to sign consent (e.g., mentally challenged, those declared legally incompetent).
• Recent use of weight loss medications (< 6 months).
• History of abdominal GI surgery other than appendectomy.
• Bleeding disorder.
• Pregnancy.
• Positive history of chronic gastrointestinal diseases, or systemic disease that could affect gastrointestinal motility, or use of medications that may alter gastrointestinal motility, appetite or absorption; e.g., orlistat, phentermine.
• Subject has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence.
• Any contraindications to MRI.
• Claustrophobia.

• Confirmed diagnosis of SCFE.
• Intend to receiving follow-up at participating centre.
• Less than 18 years old at time of admission.
• Adequate diagnostic information and radiographic imaging (for patients previously treated for SCFE).

• No definitive diagnosis of SCFE.
• Do not intend to receive follow-up at a participating centre.
• Greater than 18 years old at time of admission.
• Prior treatment for SCFE not appropriately documented.
• Known or suspected underlying conditions (e.g., cerebral palsy, spina bifida, or osteogenesis imperfecta)

Eligibility last updated 8/18/22. Questions regarding updates should be directed to the study team contact.

• Ages 0-40 years old.
• All patients with spine and/or chest wall disorders.

• Age older than 40 years old.
• Patient participates in another registry/database with the specific objective to collect pediatric spine deformity data. 
• Family does not want to participate.

• Ages 0-40 years old.
• All patients with spine and/or chest wall disorders.

• Age older than 40 years old.
• Patient participates in another registry/database with the specific objective to collect pediatric spine deformity data. 
• Family does not want to participate.

• Treated at Mayo Clinic in Radiation Oncology.
• Radiation therapy for curative intent.

• None.

• Treated at Mayo Clinic in Radiation Oncology.
• Radiation therapy for curative intent.

• None.

• Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases.
• Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
• Subject and/or parent/legal guardian can read either English or Spanish.
• Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.

• Greater than 21 years of age at the time of enrollment.

• Solid organ transplant candidates (18 years or older) on deferred, active, or inactive transplant waiting lists.
• Nominated adult caregivers (18 years or older) of solid organ transplant patients listed for deceased donor solid organ transplantation.
• CG identified in the electronic medical record.

• Individuals unwilling to provide consent.
• Patients or CG unable to complete questionnaires or consents due to limited English proficiency.

• Patients with scleroderma meeting either a, b, c, or d:
• the 2013 ACR criteria;
• 3 out of 5 CREST (calcinosis, Raynauds, esophageal dysmotility, sclerodactyly, telangiectasias);
• triad of Raynauds, nailfold capillary abnormalities, and positive scleroderma autoantibody;
• very early diagnosis of systemic sclerosis (VEDOSS) defined as Raynaud’s, puffy digits, and abnormal nailfold capillaries or positive autoantibody.
• Patients with overlapping autoimmune phenotypes may be included, provided they meet the 2013 scleroderma classification criteria (a).
• This protocol will also allow for recruitment of healthy volunteers for comparison studies.

• Patients without scleroderma will be excluded from the primary disease cohort.
• Healthy volunteers
  (for the comparison cohort) will excluded if they have any autoimmune condition(s) (rheumatic, neurologic, hematologic, etc., at the discretion of the primary investigator or co-investigators).

Eligibility last updated 12/6/21.  Questions regarding updates should be directed to the study team contact.

• Consecutive patients age 18 and older with the below diagnoses:
  • Cervical radiculopathy or cervical myelopathy;
  • Surgical patients eligible for treatment with cervical foraminotomy, cervical arthroplasty, cervical laminectomy, cervical fusion, anterior cervical discectomy and fusion, cervical laminoplasty or a combination of above.

• Individuals < 18 years of age.
• Patients diagnosed at the C1-C2 levels.

• Patients of age 18 to 65 will be asked to be in this study because they are pregnant and their fetus has hydronephrosis or if they have a child who has hydronephrosis.
• Mothers under 18 will not be enrolled.
• All children will be under the age of 6.

• Anyone who doesn’t carry the hydronephrosis condition.  
• Who denies consent.

• Patient presenting to a General Internal Medicine Service.
• Patient in one of the 3 Mayo Clinic Campuses (Rochester, Arizona, Florida).
• Patient with an undiagnosed mass: New or enlarging lymph nodes clinically or on imaging:
  • New mass on imaging of soft tissues, bone, spleen, adrenal gland, retroperitoneum, or intraabdominal location without clear organ association.
• Patient has understood and signed the informed consent to participate in the registry.
• Patient has the ability to complete all aspects of registry enrollment.
• Aged 18 and older.

• Mass involving the breast, brain, kidney, lung, ovary/adnexa, liver, pancreas, sinus, throat, or thyroid gland will be addressed by the respective specialty areas.  
• Patients with a known history of any condition or factor judged by the investigator to preclude participation in the registry or which might hinder adherence.
• Lacking the capacity to consent.
• Prisoners or institutionalized individuals.
• Pregnant women.

Eligibility last updated 9/17/21. Questions regarding updates should be directed to the study team contact.

• New patients to a PHA Care Center with either newly diagnosed or established PAH or CTEPH (within 6 months of first outpatient visit at the PHCC).
• Informed consent for data to be abstracted and included in the PHAR provided by the patient or guardian.
• Able to understand and speak either English or Spanish.

• Any exception to the Inclusion Criteria above.

• Mayo Clinic patients with suspected Familial Hypercholesterolemia (FH).
• Age ≥ 18 years.
• LDL cholesterol ≥ 190 mg/dl.
• Capable of providing informed consent.

• Lack of research authorization.
• Unable to provide informed consent.

• Patients had to be seen by a health care provider at least once at the Family Medicine and Primary Care Internal Medicine clinics of Mayo Clinic in Rochester, MN or the Mayo Clinic Health System during the study time. 
• Patients had to be empaneled to a primary care provider.
• Ability to give informed consent.
• Ability to read and speak the English language.
• Age 65 or older.

• Patients that had not to be seen by a health care provider during the study time.
• Any participant who refused medical record review.
• Incarcerated individuals.
• Hospice enrollment.
• Memory Care residents.
• Major Neurocognitive disorder (severe and moderate dementia).